OS Therapies Clarifies CUSIP of Common Stock
22 August 2024 - 12:00PM
Business Wire
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the
Company”), an ADC and Immunotherapy research and clinical-stage
biopharmaceutical company, today provided a clarification for
market participants, specifically brokerage firms, regarding the
Committee on Uniform Securities Identification Procedures (CUSIP)
identifier of the Company’s common stock.
The Company’s common stock began trading on the NYSE American on
August 1st, 2024 under CUSIP 68764Y108 (“Old CUSIP”). On August
5th, the Company completed certain matters related to a corporate
action that had occurred prior to the listing of the Company’s
common stock on the NYSE American that resulted in new CUSIP
68764Y207 (“New CUSIP”) being assigned to the Company’s common
stock. All shares sold or purchased under the Old CUSIP are now
identified as the same number of shares under the New CUSIP. No
share splits or any other similar actions occurred between August
1, 2024 and August 5, 2024.
All market participants, including brokerage firms, are hereby
notified to update their records such that shares of the Company’s
common stock listed under the Old CUSIP should be identified, sold
and purchased under the New CUSIP 68764Y207.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the
identification, development and commercialization of treatments for
Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s
lead asset, is an immunotherapy leveraging the immune-stimulatory
effects of Listeria bacteria to initiate a strong immune response
targeting the HER2 protein. The Company has completed enrollment
for a 41-patient Phase 2b clinical trial of OST-HER2 in resected,
recurrent osteosarcoma, with results expected in the fourth quarter
of 2024. OST-HER2 has completed a Phase 1 clinical study primarily
in breast cancer patients, in addition to showing strong
preclinical efficacy data in various models of breast cancer. In
addition, OS Therapies is advancing its next generation Antibody
Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which
features tunable, tailored antibody-linker-payload candidates. This
platform leverages the Company’s proprietary silicone linker
technology, enabling the delivery of multiple payloads per linker.
For more information, please visit www.ostherapies.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240822905132/en/
Corporate and Media Contact: Jack Doll 410-297-7793
Irpr@ostherapies.com
Investor Relations: Dave Gentry RedChip Companies, Inc.
1-407-644-4256 OSTX@redchip.com
OS Therapies (AMEX:OSTX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
OS Therapies (AMEX:OSTX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024